Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
Stock Information for Bellerophon Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.